Oral Mucosal Immunization Recent Advancement and Exploit Dendritic Cell Targeting
Oral mucosal vaccine thrive significant interest in developing vaccines that evoke mucosal moreover systemic immune response i.e. induction of IgA. Oral immunization consistently preferred over conventional immunization because it provides strengthens inpatient acquiescence, needle-free delivery, cost-effective. Thereby strong antibody production at the mucosal site is not refreshing by parenteral administration of the vaccines. Antibodies produced on the mucosal surface instead of it also start common mucosal immune system (CMIS). Vaccines allow particulate delivery protection of antigen. Polylactic-co-glycolic acid, poly lactic acid loaded nanoparticles, liposomes, niosomes, dendrimers; proteosomes are some of the nanocarriers which protect the antigen from their degradation. Authentication concepts of various studies on the mucosal vaccine by using nanotechnology for targeting to dendritic cell presenting on Peyer's patch elicit antibody production. This review sums up current studies on mucosal vaccination by using nanocarrier. More of the studies have been done on mucosal for improvement in methodology.
Keywords: Antigen, Nanotechnology, Dendritic cells, Peyer’s patch, Vaccine
2. Magistris MTD. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 2006; 58: 52-67.
3. Sahu KK, Pandey RS. Development, and characterization of HBsAg loaded Eudragit nanoparticles for effective colonic immunization. Pharmaceutical development and technology Rev 2018, 1-27.
4. Azegami T, Yuki Y. Challenges in mucosal vaccines for the control of infectious diseases, International immunology Rev2014; 517-28.
5. Srivastava A, Gowda VD, Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles. APMIS Rev 2015: 123(4):275-88.
6. Nizard M, Diniz OM. Mucosal vaccines. Human vaccines and immunotherapeutic Rev 2014; 10(8):2175-2187.
7. Arora D, Goyal AK, Oral mucosal immunization: Recent advancement and future prospects. Current immunology Rev.2010: 6(3):234-259.
8. K.H.G. Mills, Recognition of foreign antigen by T cells and their role in immune protection, Curr. Opin. Infect. Dis. 1989; 2:804–814.
9. MC Neela, Mills GH. Manipulating the immune system: humoral vs. cell-mediated immunity, advanced drug delivery Rev2001: 43-54.
10. F.W. van Ginkel, H.H. Nguyen. Vaccines for mucosal immunity to combat emerging infectious diseases, Emerge. Infect. Dis. 2000; 6:123–132.
11. Engels Niklas, Wienands Jurgen. Memory control by the B cell antigen receptor, Wiley immunological rev 2018: 283(1):150-160.
12. Cruvinel MW, Junior MD. Fundamentals of innate immunity with emphasis on the molecular & cellular mech. Of inflammatory response, bras J Rheumatol 2010: 434-61.
13. Delves PJ, Roitt D. The Immune System – First of two parts. N Engl J Med 2000; 343:37-50.
14. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-69.
15. Banchereau J, Briere F. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
16. Neutra RM and Kozlowski AP. Mucosal vaccines: the promise and the challenge Nat Rev.immunol6, Rev2006; 6(2): 148-58.
17. Cook IF. Evidence-based route of administration of vaccines, Human vaccines Riv.2008, 4:1, 67-73.
18. Herzog Christian. The influence of parenteral administration route and additional factors on vaccine safety and immunogenicity: a review of recent literature, expert review vaccines 2014; 13(3):399-415.
19. Irvine RK. Chamberlain RS. Route of immunization and the therapeutic impact of recombinant anticancer vaccines, a journal of the national cancer institute vol. 89.Rev.1995.
20. Kozlowski AP, Uvin CS. Comparison of the oral, rectal and vaginal immunization routes for induction of antibodies in rectal and genital tract secretion for women, Infection and immunity Rev.1997; 1387-1394.
21. Zhu Qing, Berzofsky AJ. Directed safe passage to the front line of defense, gut microbes Rev2013, 4(3):246-252.
22. Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine, BMC biology Rev. 2010; 8:129.
23. XuB, Zhang W, Chen Y. EudragitL100- coated mannosylated chitosan nanoparticles for oral protein vaccine delivery, Biological macromolecules rev 2018; 113:534-542.
24. Kim HS, Kim NH. C5a receptor targeting of partial nonstructural protein 3 of dengue virus promotes antigen-specific IFNˠ producing T cell responses in mucosal dengue vaccine model, cellular immunology Rev 2018: 325:41-47
25. Zhang R, Wang C. Delivery of Helicobacter pylori HPaA to gastrointestinal mucosal immune sites using Lactococcus lactis and its immune efficacy in mice, Biotechnol Lett Rev.2018 40(3): 585-590.
26. Ouchida NR, Yuki Y. Development of nanogel based nasal vaccine as a novel antigen delivery system, Expert review of vaccines Rev.2017 16(12): 1231-1240.
27. Vemireddy S, MC, Kumar SMH. Chitosan stabilized nasal emulsion delivery system for an effective humoral and cellular response against recombinant tetravalent dengue antigen, carbohydrate polymers Rev.2018, 190:129-138.
28. Lopes DP, OkinoHC. Inactivated infectious bronchitis virus vaccine encapsulated in chitosan nanoparticles induces mucosal immune responses and effective protection against challenge, Vaccine, Rev 2018: 2630-2636.
29. Thomas Manjaly RZ, Mcshane H. Aerosol immunization for TB: matching route of vaccination to route of infection, TransR SocRev2015, 109:175-181.
30. Juarez LM, Kirkpatrick TC. Combined aerosolized toll-like receptor ligand are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir, European journal of pharmacology Rev.2018: 191-197.
31. Ortega DL, Castaneda D. Antibody persistence in children aged 6-7 years one year following booster immunization with two MMR vaccines applied by aerosol or by injection, Vaccine Rev2017, 35(23): 3116-3122.
32. Premjeet S, Sahil K. Transcutaneous drug delivery system: A comprehensive review, IRJP Rev.2011: 2(12):49-55.
33. Wakabayashi R, Sakuragi M. Solid-in oil peptide nanocarrier for Transcutaneous cancer vaccine delivery against melanoma, molecular pharmaceutics Rev.2018, 15(3):955-981.
34. Lopez AP, Denny M. Transcutaneous immunization with a novel imiquimod Nanoemulsion induces superior T cell responses and virus protection.
35. Czerkinsky C, Holmgren J, Mucosal delivery routes for optimal immunization: targeting immunity to the right tissue, Microbiology and immunology Rev.2010: 1-18.
36. Kraan H, Vrieling H. Buccal and sublingual vaccine delivery, Journal of controlled release Rev2014:580-592
37. Nagai Y, Shiraishi D. Transportation of sublingual antigens across sublingual ductal epithelial cells to the ductal antigen presenting cells in mice, a Basic mechanism in allergic disease Rev.2013: 1-25.
38. Hamman JH, Enslin GM. Oral delivery of peptide drugs barriers and developments, Bio drugs Rev.2005: 19(3):165-77.
39. Engman H. Intestinal barriers to oral drug absorption: cytochrome P4503A and ABC- transport proteins, Rev.2003, 296.61.
40. Song NN, Zhang YS. an overview of factors affecting oral drug absorption, Asian journal of drug metabolism and pharmacokinetics Rev. 2004; 4(3): 167-176.
41. Renukuntla J, Vadlapudi DA. Approaches for enhancing oral bioavailability of peptides and proteins, International journal of pharmaceutics Rev.2013: 75-93.
42. Zhou HX. Overcoming enzymatic and absorption barriers to non parenterally administered protein and peptide drugs, controlled release Rev.1994: 239-252.
43. Khodabandehloo H. Nanocarriers usage for drug delivery in cancer therapy, Cancer prevention Rev.2016, 9(2): 3966.
44. Mody N, Sharma R. Capsaicin-loaded vesicular systems designed for enhancing localized delivery for psoriasis therapy, Therapeutics delivery Rev.2015 6(2), 231-245.
45. Laborde RJ, Ferras SO. Novel adjuvant based on the pore-forming protein sticholysin encapsulated into liposomes effectively enhances the antigen-specific CTL- mediated immune response, immunology Rev.2018 198(7): 2772-2784.
46. Talesh GA, Ebrahimi Z. Poly (I:C)- DOTAP cationic nanoliposomes containing multi epitope HER2-derived peptide promoters vaccine elicited anti tumour immunity in a murine model, Immunology letters Rev.2016: 176, 57-64.
47. Kawai K, Miyazaki J. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine, cancer science Rev.2013: 104, 22-27.
48. Moignic AL, Mallard V. Preclinical evaluation of mRNA Trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells, controlled release Rev.2018, 6; 278: 110-121
49. Nekkanti V, Kale S. Recent advances in liposomal drug delivery: A review, Pharmaceutical nanotechnology Rev.2015, 35-55(21).
50. Jadhav MS, Morey P, Novel vesicular system: an overview, JAPS Rev.2012: 193-202.
51. Mohamed BH, Shanawany SE. Niosomes: A strategy towards prevention of clinically significant drug incompatibilities, Scientific reports Rev2017, 6340.
52. Prasad V, Chaurasia S. Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis, materials science and engineering C Rev 2017 168-176.
53. Sahoo KR, Biswas N. Development and in vitro/ in vivo evaluation of controlled release Provesicles of a nateglinide- maltodextrin complex, APSB Rev.2014: 408-416.
54. Abidin L, Mujeeb M, Imam SS. Enhanced transdermal delivery of luteolin via non-ionic surfactant based vesicle: quality evaluation and anti-arthritic assessment, drug delivery Rev2014; 23(3): 1079-84.
55. Maheshwari C, Pandey RS.Non-ionic surfactant vesicles mediated Transcutaneous immunization against Hepatitis B, International immunopharmacology Rev.2011: 1516-1522.
56. Mann FS, Scales EH. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity, Science direct rev.2006: 90-95.
57. Conacher M, Alexander J. Oral immunization with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes), Vaccines Rev2001: 2965-2974.
58. Arora daisy, Khurana Bharat. Oral immunization against Hepatitis B virus using mannosylated bilosomes, J. Of recent advance in pharmaceutical research Rev2011, 1:45-51.
59. Shukla A, Katare OP. Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using Nano- bilosomes, BJP rev.2011: 164, 820-827.
60. Singh P, Vyas SP. Cholera toxin B subunit conjugated bile salts stabilized vesicles (bilosomes) for oral immunization, International journal of pharmaceutics Rev.2004: 379-390.
61. Deepika B, Kumar MS. Development of Leishmania donovani antigen-loaded mannosylated bilosomes to target M cell: In vitro characterization, World journal of pharmacy and pharmaceutical research Rev.2014: Vol (3): 1983-1999.
62. Sahu KK, Pandey RS, Development and characterization of HBsAg loaded Eudragit nanoparticles for effective colonic immunization, Pharmaceutical development, and technology Rev.2018: 1-10.
63. Cao Xi, Ye Ql. A self-assembling anticaries mucosal vaccine containing ferritin cage nanostructure and glucan binding region of S.mutans glucosyl transferase effectively prevents caries formation in rodents, Human vaccines, and immunotherapeutic Rev.2017: 1-29.
64. Kaur M, Malik B. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis, Drug delivery Rev2014: 1-7.
65. Harde H, Agrawal AK. Tetanus toxoid loaded glucomannosylated chitosan-based nano homing vaccine adjuvants with improved oral stability and immunostimulatory response, pharmacies, Rev.2015: 32(1): 122-34.
66. Jaiswal M, Dudhe R. Nanoemulsion: An advanced mode of drug delivery system, Biotech Rev.2015 5(2): 123-127.
67. Konek J, Landers JJ. Nanoemulsion adjuvant driven redirection of TH2 immunity inhibits allergic reactions in murine models of peanut allergy, J Allergy Clin Immunol Rev.2018. 1-11.
68. Bielinska AU, Janczak WK. Mucosal immunization with a novel Nanoemulsion based recombinant anthrax protective antigen vaccine protects against B. Anthrax spore challenge, Infectious immunology Rev.2007: 1-45.
69. Makidon PE, Bielinska AU. Preclinical evaluation of novel Nanoemulsion based Hepatitis B mucosal vaccine, PLOS ONE3 (8) Rev.2008: 1-16.
70. Patravale V, jain R. Nanoemulsion: an overview, Science direct Rev.2016: 1-13.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).